Trials / Not Yet Recruiting
Not Yet RecruitingNCT06433609
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 131 (estimated)
- Sponsor
- Beijing GoBroad Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811 and SHR-A1921 combined with adebrelimab in HER2-negative advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811 | Via intravenous infusion |
| DRUG | SHR-A1921 | Via intravenous infusion |
| DRUG | Adebrelimab | Via intravenous infusion |
Timeline
- Start date
- 2024-06-01
- Primary completion
- 2027-07-01
- Completion
- 2027-11-01
- First posted
- 2024-05-30
- Last updated
- 2024-05-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06433609. Inclusion in this directory is not an endorsement.